Form 4: NovoCure Director Allyson J. Ocean Receives Equity Compensation Grant

NovoCure Ltd. Director Allyson J. Ocean was granted 11,215 restricted stock units and options to purchase 16,697 ordinary shares as part of her compensation, aligning her interests with shareholders.

Summary

• Allyson J. Ocean, a Director of NovoCure Ltd. (NVCR), reported the acquisition of equity securities on June 4, 2025.
• She was granted 11,215 Ordinary Shares in the form of Restricted Stock Units (RSUs) at a price of $0.00 per share.
• These RSUs are scheduled to vest 100% on the earlier of the first anniversary of the grant date or the day immediately preceding the Company's 2026 annual general meeting of shareholders.
• Following this transaction, Ms. Ocean beneficially owns 14,269 Ordinary Shares directly.
• Additionally, Ms. Ocean was granted Stock Options (Right to Buy) for 16,697 Ordinary Shares with an exercise price of $16.72 per share.
• These stock options will fully vest and become exercisable on the earlier of the first anniversary of the grant date or the day immediately preceding the Company's 2026 annual general meeting of shareholders.
• The stock options have an expiration date of June 4, 2035.
• Following this transaction, Ms. Ocean beneficially owns 16,697 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the equity grant aligns the director's interests with shareholders, which is generally viewed favorably for corporate governance and long-term value creation. It's a routine compensation event, not indicative of specific operational performance.

Positives

• The grant of restricted stock units and stock options to Director Allyson J. Ocean aligns her financial interests with those of the company's shareholders, promoting long-term value creation.
• Equity compensation is a standard practice for attracting and retaining qualified board members in publicly traded companies.

Future Outlook

The granted restricted stock units and stock options are scheduled to vest on the earlier of June 4, 2026, or the day immediately preceding the Company's 2026 annual general meeting of shareholders, indicating future equity ownership and potential exercise events.

Industry Context

The granting of equity compensation, such as restricted stock units and stock options, to non-employee directors is a common and widely accepted practice across various industries, including the biotechnology and medical device sectors where NovoCure operates. This method of compensation is designed to incentivize directors to contribute to the company's long-term success and align their financial interests with those of shareholders.

Comparison to Industry Standards

• Granting equity compensation (RSUs and stock options) to non-employee directors is a standard practice among publicly traded companies, including those in the healthcare and biotechnology sectors, to align director incentives with shareholder value.
• The vesting schedule, tied to either a one-year anniversary or the next annual general meeting, is typical for director equity grants, ensuring continued service and commitment.

Stakeholder Impact

• Shareholders: The equity grant to a director aims to align their interests with shareholders, potentially leading to better long-term decision-making and value creation.

Next Steps

• The restricted stock units and stock options are scheduled to vest on the earlier of June 4, 2026, or the day immediately preceding the Company's 2026 annual general meeting of shareholders.
• Upon vesting, the stock options will become exercisable, allowing Allyson J. Ocean to purchase ordinary shares at the exercise price of $16.72.

Key Dates

Keywords

NovoCure, NVCR, SEC Form 4, Insider Transaction, Director Compensation, Restricted Stock Units, Stock Options, Equity Grant, Beneficial Ownership